Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(166 produits)
- Bcr-Abl(117 produits)
- EGFR(551 produits)
- FAK(72 produits)
- FLT(88 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(176 produits)
- JAK(243 produits)
- PDGFR(127 produits)
- RAAS(86 produits)
- Src(82 produits)
- Syk(37 produits)
- Thrombine(51 produits)
- VDA(2 produits)
- VEGFR(236 produits)
Affichez 6 plus de sous-catégories
2267 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
ES-072
CAS :ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.Formule :C25H27F3N8O2Couleur et forme :SolidMasse moléculaire :528.53BTK inhibitor 18
BTK inhibitor 18 is a selective, potent, covalent, orally active Btk inhibitor (IC50: 142 nM) that exhibits anti-inflammatory effects.Formule :C29H25N5O4S2Couleur et forme :SolidMasse moléculaire :571.67JAK1-IN-9
CAS :JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.Formule :C16H13IN6Couleur et forme :SolidMasse moléculaire :416.22GLPG3312
CAS :GLPG3312 is a selective and potent pan-SIK inhibitor with the advantage of oral activity, for SIK1, SIK2 and SIK3, anti-inflammatory and immunomodulatory .Formule :C23H21F2N5O3Degré de pureté :98.53%Couleur et forme :SolidMasse moléculaire :453.44SST0116CL1
CAS :SST0116CL1 is an HSP90 inhibitor (IC50: 0.21 μM) that targets the ATP-binding pocket of Hsp90, disrupting its chaperone function and leading to the degradation of client proteins (EGFR, CDK4, and AKT). It induces the degradation of Her2 in BT-474 cells (IC50: 0.2 μM) and exhibits antiproliferative activity, inhibiting tumor growth.Formule :C22H31ClN4O6Couleur et forme :SolidMasse moléculaire :482.96EG31
CAS :EG31 is an EGFR inhibitor that effectively suppresses the proliferation of triple-negative breast cancer (TNBC) cells by inhibiting the EGFR signaling pathway. It demonstrates a GI50 value of 498.90 nM for MDA-MB-231 cells and 740.73 nM for Hs578T cells, while also inducing apoptosis. Additionally, EG31 retains its antiproliferative activity against 5-fluorouracil (5-FU) resistant TNBC cells, with a GI50 of 519.5 nM. EG31 is applicable in research on TNBC resistance.Formule :C30H13Br2N3O6Couleur et forme :SolidMasse moléculaire :671.25FAK inhibitor 6
CAS :Compound 26F: potent enzyme inhibitor (IC50=28.2nM), low cytotoxicity (IC50=3.32μM), induces dose-dependent apoptosis in MDA-MB-231, blocks G0/G1 phase.Formule :C25H24FN5O2SCouleur et forme :SolidMasse moléculaire :477.55Neptinib
CAS :Neptinib (NEP010), a derivative of Afatinib, exhibits enhanced antitumor properties and improved pharmacokinetics when administered orally. It demonstrates a notable suppression of tumor expansion in mouse models of non-small cell lung cancer harboring various EGFR mutations. Furthermore, Neptinib effectively inhibits the EGFR kinase family, exhibiting IC 50 values of 0.24 nM for EGFR wt, 7.25 nM for EGFR L858R/T790M, 0.46 nM for EGFR L858R, and 1.79 nM for EGFR T790M.Formule :C22H23ClFN5O2Couleur et forme :SolidMasse moléculaire :443.90JAK/HDAC-IN-3
CAS :JAK/HDAC-IN-3 (13a), a dual inhibitor of JAK and HDAC, exhibits IC50 values of 25.36 nM for JAK2, 0.2 μM for HDAC, and 0.43 μM for HDAC1, respectively [1].Formule :C28H37FN6O5SCouleur et forme :SolidMasse moléculaire :588.69Tyk2-IN-15
CAS :Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].
Formule :C21H25F2N7OCouleur et forme :SolidMasse moléculaire :429.47Tyk2-IN-14
CAS :Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].Formule :C22H21N9O2Couleur et forme :SolidMasse moléculaire :443.46EGFR-IN-160
CAS :EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).Formule :C15H12N2O4Couleur et forme :SolidMasse moléculaire :284.27JAK1/TYK2-IN-4
CAS :JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].Formule :C17H23N7OCouleur et forme :SolidMasse moléculaire :341.41Tyk2-IN-17
CAS :Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].Formule :C20H20F2N8OCouleur et forme :SolidMasse moléculaire :426.42JAK2-IN-11
CAS :JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.Formule :C31H31F3N8O4Couleur et forme :SolidMasse moléculaire :639.64PNU-145156E
CAS :PNU-145156E is a noncytotoxic molecule inhibiting growth and angiogenic factors, suppress tumor angiogenesis, support anti-angiogenic research strategies.Formule :C45H40N10O17S4Couleur et forme :SolidMasse moléculaire :1121.12Lazertinib mesylate
CAS :Lazertinib (mesylate) (YH25448 (mesylate); GNS-1480 (mesylate)) is an orally active EGFR inhibitor capable of crossing the blood-brain barrier. It suppresses the p-EGFR, p-AKT, and p-ERK signaling pathways, leading to apoptosis. Lazertinib (mesylate) demonstrates antitumor activity in the H1975-luc BM xenograft model in mice and is applicable for researching non-small cell lung cancer.
Formule :C31H38N8O6SMasse moléculaire :650.75ALK/PI3K/AKT-IN-1
CAS :ALK/PI3K/AKT-IN-1 (Compound 45) effectively inhibits the proliferation of cancer cell lines A549, H1975, and PC9, with IC50 values of 0.44, 0.83, and 1.51 μM, respectively. This compound enhances the expression of p21 and p27, and decreases the activity of CDK2 and p-Rb, causing cell cycle arrest at the G1 phase. It suppresses the ALK/PI3K/AKT signaling pathway, promotes mitochondrial membrane potential depolarization, and induces apoptosis in A549 cells. Furthermore, ALK/PI3K/AKT-IN-1 inhibits the formation and growth of A549 cell spheres.Formule :C25H20FN5O2SCouleur et forme :SolidMasse moléculaire :473.522Ki11502
CAS :Ki11502 is a multi-target receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the activity of PDGFβ/α receptors (with an IC50 of less than 10 nM). It specifically suppresses PDGFβ receptor phosphorylation, proliferation, and proteoglycan synthesis in human vascular smooth muscle cells. Additionally, Ki11502 induces apoptosis and exhibits significant antiproliferative effects against specific leukemia subgroups, including those with Imatinib-resistant mutations. It is particularly suitable for studying the role of PDGF in vascular diseases and the involvement of proteoglycans in atherosclerosis.Formule :C26H23N3O4SMasse moléculaire :473.54FAK-IN-2
FAK-IN-2: potent oral FAK inhibitor, IC50 35 nM, reduces tumor growth, migration, and induces cell death.Formule :C28H31ClN8O3Couleur et forme :SolidMasse moléculaire :563.05JBJ-02-112-05
CAS :JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].Formule :C27H20N4O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :464.54CDD-1115
CAS :CDD-1115 is a potent and selective BMPR2 inhibitor, with an IC50 of 1.8 nM and a Kiapp of 6.2 nM. It effectively suppresses gene expression mediated by bone morphogenetic proteins (BMPs). BMPs regulate cellular processes in various tissue types, such as the kidneys, skeletal muscle, heart, and reproductive organs, and can induce ectopic bone formation.Formule :C32H30N6O3Couleur et forme :SolidMasse moléculaire :546.619VEGFR-2-IN-5 hydrochloride
VEGFR-2-IN-5 hydrochloride is an effective VEGFR2 inhibitor.Formule :C19H25ClN8Couleur et forme :SolidMasse moléculaire :400.91JBJ-09-063
CAS :JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.Formule :C31H29FN4O3SCouleur et forme :SolidMasse moléculaire :556.65FAK-IN-6
FAK-IN-6: Potent FAK inhibitor (IC50=1.415 nM), anti-cancer, for pancreatic studies.Formule :C25H31ClN5O6PSCouleur et forme :SolidMasse moléculaire :596.04ALK-IN-31
CAS :ALK-IN-31 (Compound Ld-10) is an orally active ALK inhibitor with an IC50 of 1135 nM. It demonstrates excellent antiproliferative activity against lung cancer cells H2228, with an IC50 value of 1.35 μM. ALK-IN-31 induces apoptosis and arrests cell proliferation at the G0/G1 phase by affecting mitochondrial function. It exhibits antitumor effects by downregulating the expression of p-AKT and p-mTOR in the PI3K-AKT-mTOR signaling pathway downstream of ALK. This compound is applicable for research into non-small cell lung cancer (NSCLC).Formule :C30H33N5O2SCouleur et forme :SolidMasse moléculaire :527.68RGB-286638
CAS :RGB-286638 inhibits multiple CDKs and GSK-3β, TAK1, Jak2, MEK1 with IC50s as low as 1-54 nM.Formule :C29H37Cl2N7O4Couleur et forme :SolidMasse moléculaire :618.55LSD1/EGFR-IN-1
CAS :LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.
Formule :C21H20ClN3O4Couleur et forme :SolidMasse moléculaire :413.854JNJ-47117096
CAS :JNJ-47117096 is a potent and selective MELK inhibitor with an IC50 of 23 nM, and it also exhibits strong activity against Flt3 with an IC50 of 18 nM.Formule :C21H22N4O2Couleur et forme :SolidMasse moléculaire :362.425EGFR-IN-48
EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.Couleur et forme :SolidBMS-066
CAS :BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor. With IC50s of 9 nM and 72 nM, respectively.Formule :C19H21N7O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :379.42Squalamine
CAS :Squalamine is an aminosterol compound, with potent broad spectrum antiviral activity.Formule :C34H65N3O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :627.96FGFR4-IN-10
FGFR4-IN-10 (compound 5a) is a potent, selective FGFR4 inhibitor with IC50 of 70.7 nM, sparing FGFR1-3.Formule :C20H19F3N6O3Couleur et forme :SolidMasse moléculaire :448.4ALKBH5-IN-3
CAS :ALKBH5-IN-3 (Compound 20m) is a selective ALKBH5 inhibitor (IC50=21 nM), effectively stabilizes ALKBH5 in HepG2 cells and elevates m6A levels in intact cells.Formule :C11H7F3N2O3Degré de pureté :98.32%Couleur et forme :SolidMasse moléculaire :272.18TYK2 ligand 2
CAS :TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.Formule :C24H20FN7O4Couleur et forme :SolidMasse moléculaire :489.458BTK-IN-15
BTK-IN-15: Oral BTK inhibitor, IC50 0.7 nM, induces cancer cell apoptosis, selective with anti-tumor effects.Formule :C28H24FN5O2Couleur et forme :SolidMasse moléculaire :481.52I194496
CAS :I194496 is an effective inhibitor of cystathionine γ-lyase (CSE) with an IC50 value of 0.79 mM. It inhibits the growth of human TNBC cells by dual targeting the PI3K/Akt and Ras/Raf/ERK pathways. Additionally, I194496 suppresses the metastasis of human TNBC cells by downregulating the Anxa2/STAT3 and VEGF/FAK/Paxillin signaling pathways.Formule :C28H23F2N5O5SCouleur et forme :SolidMasse moléculaire :579.58SYHA1815
CAS :SYHA1815, an orally active RET inhibitor (IC50=0.9 nmol/L), demonstrates antitumor activity. It exhibits greater selectivity for RET over KDR (IC50=15.9 nmol/L). SYHA1815 operates by downregulating c-Myc, arresting the G1 cell cycle, and inhibiting RET-driven cell proliferation.Formule :C27H26ClF4N5OCouleur et forme :SolidMasse moléculaire :547.98FGFR-IN-6
CAS :FGFR-IN-6 (Compound 5) is an FGFR inhibitor.Formule :C23H22N6O3Couleur et forme :SolidMasse moléculaire :430.46CLM3
CAS :CLM3, a pyrazolopyrimidine derivative, functions as a multitargeted tyrosine kinase inhibitor. It exhibits antiproliferative and proapoptotic activities on endothelial and cancer cells, activities that are synergistically enhanced by SN38. The primary mechanism of action for CLM3 involves the inhibition of phosphorylation in tyrosine kinases such as VEGFR-2, EGFR, and RET, along with their associated signaling pathways.Formule :C21H21N5Couleur et forme :SolidMasse moléculaire :343.43Multi-kinase inhibitor 3
CAS :Multi-kinase inhibitor 3 (compound 12) is an orally active and effective multikinase (multikinase) inhibitor, demonstrating potent IC50 values against FLT1/VEGFR1, KDR/VEGFR2, FLT4/VEGFR3, FLT3, PDGFRα, and PDGFRβ, at 1.59, 1.23, 1.19, 0.59, 0.22, and 1.15 nM respectively. This compound exhibits anti-proliferative and anticancer activities.Formule :C26H26N6O2Couleur et forme :SolidMasse moléculaire :454.52Tyrphostin 63
CAS :Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.Formule :C10H8N2OCouleur et forme :SolidMasse moléculaire :172.183SILA-123
CAS :SILA-123, an inhibitor of FLT3 (FLT3-WT: IC50=2.1 nM; FLT3-ITD: IC50=1.0 nM), induces cell apoptosis by hindering the cell cycle progression at the G0/G1 phase through the suppression of FLT3 phosphorylation and its downstream signaling pathways. This compound is utilized in the study of acute myeloid leukemia.Formule :C24H25N5O2Couleur et forme :SolidMasse moléculaire :415.49iBFAR2
CAS :iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.
Formule :C19H15F3N2O2Couleur et forme :SolidMasse moléculaire :360.33YSY01A
CAS :YSY01A is a proteasome inhibitor that suppresses cancer cell survival by inducing apoptosis (Apoptosis). It demonstrates IC50 values against various cell lines such as HEK293T, A549, MCF-7, MGC-803, and PC-3M with values of 51.01, 9.21, 5.21, 8.9, and 35.4 nM respectively. Additionally, YSY01A serves as a degrader of gp130 and JAK2, eliminating constitutive STAT3 signaling in human A549 lung cancer cells by downregulating gp130 and JAK2. YSY01A holds potential for research in cancer therapeutics.Formule :C29H38BN5O5Couleur et forme :SolidMasse moléculaire :547.45Multi-kinase inhibitor 4
CAS :Multi-kinase inhibitor 4 (compound 14) serves as an orally effective inhibitor targeting FLT1, KDR, FLT3, FLT4, PDGFRα, and PDGFRβ, exhibiting IC50 values of 1.97 nM, 1.04 nM, 0.33 nM, 1.44 nM, 0.18 nM, and 0.89 nM respectively. This compound plays a crucial role in cancer research.Formule :C25H24N6O2Couleur et forme :SolidMasse moléculaire :440.50NDI-034858
CAS :NDI-034858 (TAK-279) is a tyrosine kinase 2 (TYK2) inhibitor (Kd<200 pM) that targets the JH2 structural domain of Tyk2 for the treatment of autoimmune diseasesFormule :C23H24N8O3Degré de pureté :>99.99%Couleur et forme :SolidMasse moléculaire :460.49Vatalanib hydrochloride
CAS :Vatalanib hydrochloride (PTK787 hydrochloride) is an orally available and highly potent tyrosine kinase (VEGF) inhibitor that reduces the number and size of Aβ plaques in the cortex of 5xFAD mice, which may be useful in the study of Alzheimer's disease and cancer.Formule :C20H16Cl2N4Degré de pureté :99.7%Couleur et forme :SolidMasse moléculaire :383.27JAK2-IN-7
CAS :JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.Formule :C26H33N7ODegré de pureté :99.54%Couleur et forme :SolidMasse moléculaire :459.59Ref: TM-T35900
1mg145,00€5mg354,00€10mg630,00€25mg1.301,00€50mg1.738,00€100mg2.357,00€1mL*10mM (DMSO)358,00€JDTic
CAS :JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.Formule :C28H39N3O3Couleur et forme :SolidMasse moléculaire :465.63XMD-17-51 Trifluoroacetate
CAS :XMD-17-51 Trifluoroacetate is a pyrimido-diazepinone compound that regulates protein kinases.Formule :C23H25F3N8O3Degré de pureté :99.65%Couleur et forme :SolidMasse moléculaire :518.49Ibrutinib Racemate
CAS :Ibrutinib is a selective, irreversible Btk inhibitor (IC50: 0.5 nM). Ibrutinib Racemate is the racemate of Ibrutinib.Formule :C25H24N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :440.5XMU-MP-3
CAS :XMU-MP-3 is a robust, non-covalent inhibitor of BTK, exhibiting exceptional potency with IC50 values of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutation, respectively, in the presence of 10 μM ATP. Moreover, XMU-MP-3 elicits apoptosis.Formule :C27H27F3N8OCouleur et forme :SolidMasse moléculaire :536.563PM-8002
PM-8002 is a bispecific antibody that targets PD-L1 and VEGF-A. It is applicable for research on solid tumors.
Couleur et forme :Odour LiquidTLC9995-0188
CAS :Tyrosine-protein kinase ABL, IC50: 1500 nMFormule :C16H15N5Couleur et forme :Yellow SolidMasse moléculaire :277.331Nimotuzumab (powder)
CAS :Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.
Couleur et forme :LiquidHMBD-001
HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.
Couleur et forme :Odour LiquidImbotolimod
Imbotolimod, a humanized monoclonal antibody of the immunoglobulin G1-kappa class, exhibits both anti-ERBB2 and antineoplastic activities.Couleur et forme :Odour Liquid(3R,4S)-Tofacitinib
CAS :(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.Formule :C16H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :312.37Dihydrodiol-Ibrutinib
CAS :PCI 45227 is an active metabolite of the Bruton's tyrosine kinase inhibitor ibrutinib .1PCI 45227 is formed from ibrutinib by the cytochrome P450 (CYP) isoform CYP3A. 1.Veeraraghavan, S., Viswanadha, S., Thappali, S., et al.Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic studyJ. Pharm. Biomed. Anal.107151-158(2015)Formule :C25H26N6O4Couleur et forme :SolidMasse moléculaire :474.521ENMD-2076 tartrate
CAS :ENMD-2076 is an orally active kinase inhibitor. It also has antiangiogenic and antiproliferative mechanisms of action.Formule :C25H31N7O6Couleur et forme :SolidMasse moléculaire :525.56Olmutinib
CAS :Olmutinib (BI1482694) is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorFormule :C26H26N6O2SDegré de pureté :99.14%Couleur et forme :SolidMasse moléculaire :486.59Desidustat
CAS :Desidustat is an inhibitor of HIF hydroxylase.
Formule :C16H16N2O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :332.31Ref: TM-T5176
Produit arrêtéPF-03814735
CAS :PF-03814735 is a novel, potent and reversible inhibitor of Aurora A/B with IC50of 0.8 nM/5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and FGFR1. Phase 1.Formule :C23H25F3N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :474.48Duligotuzumab
CAS :Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.
Degré de pureté :95%Couleur et forme :Liquid3,3',4,4'-Tetrabromobiphenyl
CAS :Produit contrôléApplications 3,3',4,4'-Tetrabromobiphenyl is multi-persistent organic pollutants analyzed in breast milk of first time mothers. An environmental pollutant that affects copper and molybdenum metabolism in rats. Also, it is derived from 1-Bromo-2- nitrobenze (B686175), which is an organic building block used for the synthesis of various pharmaceutical compounds. It is an intermediate for the synthesis of novel Diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity.
References Tlustos, C., et al.: Organohalogen Compd., 75, 1185-1188 (2013); Salman, K. N., et al.: Environ. Sci. Pollut. R., 21, 6400-6409 (2014); Dao, P., et al.: Bioorg. Med. Chem. Lett., 23, 4552 (2013);Formule :C12H6Br4Couleur et forme :Off-White To Light BrownMasse moléculaire :469.79VEGFR-IN-1
CAS :VEGFR inhibitorFormule :C19H16ClN3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :337.8
